Advertisement

Clinical Pharmacokinetics

, Volume 48, Issue 5, pp 343–344 | Cite as

Therapeutic Drug Monitoring of Aminoglycosides in Neonates

  • Matthijs de Hoog
  • John N. van den Anker
Correspondence
  • 99 Downloads

Keywords

Hearing Loss Aminoglycosides Predictive Performance Therapeutic Drug Monitoring Pharmacokinetic Behaviour 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 2009; 48(2): 71–88PubMedCrossRefGoogle Scholar
  2. 2.
    Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155(1): 93–9PubMedCrossRefGoogle Scholar
  3. 3.
    Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2006; (1): CD005091PubMedGoogle Scholar
  4. 4.
    Nestaas E, Bangstad HJ, Sandvik L, et al. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 2005 Jul; 90(4): F294–300PubMedCrossRefGoogle Scholar
  5. 5.
    Giapros VI, Andronikou S, Cholevas VI, et al. Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 1995; 9(2): 163–6PubMedCrossRefGoogle Scholar
  6. 6.
    Borradori C, Fawer CL, Buclin T, et al. Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate 1997; 71(1): 1–10PubMedGoogle Scholar
  7. 7.
    de Hoog M, van Zanten BA, Hop WC, et al. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J Pediatr 2003 Jan; 142(1): 41–6PubMedCrossRefGoogle Scholar
  8. 8.
    de Hoog M, Mouton JW, Schoemaker RC, et al. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 2002 May; 71(5): 349–58PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Matthijs de Hoog
    • 1
  • John N. van den Anker
    • 1
    • 2
  1. 1.Intensive Care Unit, Department of Pediatrics, Erasmus Medical CenterSophia Children’s HospitalRotterdamthe Netherlands
  2. 2.Departments of Pediatrics, Pharmacology and PhysiologyChildren’s National Medical Center/George Washington University School of Medicine and Health SciencesUSA

Personalised recommendations